Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study

Psychiatry Research - Neuroimaging

Volumn 173, Issue 2, 2009, Pages 143-149

  Kaufman, Marc J ^a   Prescot, Andrew P ^a   Ongur, Dost ^a   Evins, A Eden ^b   Barros, Tanya L ^a   Medeiros, Carissa L ^a   Covell, Julie ^a   Wang, Liqun ^c   Fava, Maurizio ^b   Renshaw, Perry F ^a,d  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Antipsychotic; Glutamate receptors; Schizophrenia; Substance abuse

Indexed keywords

CREATINE; GLUTAMIC ACID; GLYCINE; GLYCINE AGONIST; GLYCINE TRANSPORTER; GLYCINE TRANSPORTER INHIBITOR; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DYNAMICS; EVENING DOSAGE; EVOKED RESPONSE; HUMAN; MALE; MORNING DOSAGE; NAUSEA AND VOMITING; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN DEFECT; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; BRAIN; CREATINE; GLYCINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; OCCIPITAL LOBE; PROTONS;

EID: 67651083407     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2009.03.004     Document Type: Article

References (70)

1. Aprison M.H., Shank R.P., and Davidoff R.A. A comparison of the concentration of glycine, a transmitter suspect, in different areas of the brain and spinal cord in seven different vertebrates. Comparative Biochemistry and Physiology 28 (1969) 1345-1355
2. Backstrom P., and Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31 (2006) 778-786
3. Behar K.L., Rothman D.L., Spencer D.D., and Petroff O.A. Analysis of macromolecule resonances in 1H NMR spectra of human brain. Magnetic Resonance in Medicine 32 (1994) 294-302
4. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 15730-15734
5. Billups D., and Attwell D. Active release of glycine or D-serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse. European Journal of Neuroscience 18 (2003) 2975-2980
6. Bisaga A., and Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug and Alcohol Dependence 59 (2000) 1-15
7. Boulay D., Pichat P., Dargazanli G., Estenne-Bouhtou G., Terranova J.P., Rogacki N., Stemmelin J., Coste A., Lanneau C., Desvignes C., Cohen C., Alonso R., Vigé X., Biton B., Steinberg R., Sevrin M., Oury-Donat F., George P., Bergis O., Griebel G., Avenet P., and Scatton B. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacology, Biochemistry and Behavior 91 (2008) 47-58
8. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., and Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 164 (2007) 1593-1602
9. Choi C., Bhardwaj P.P., Seres P., Kalra S., Tibbo P.G., and Coupland N.J. Measurement of glycine in human brain by triple refocusing 1H-MRS in vivo at 3.0T. Magnetic Resonance in Medicine 59 (2008) 59-64
10. Costa J., Khaled E., Sramek J., Bunney Jr. W., and Potkin S.G. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology 10 (1990) 71-72
11. Coyle J.T. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotoxicity Research 10 (2006) 221-233
12. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P., and Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
13. Dopico J.G., Gonzalez-Hernandez T., Perez I.M., Garcia I.G., Abril A.M., Inchausti J.O., and Rodríguez Díaz M. Glycine release in the substantia nigra: interaction with glutamate and GABA. Neuropharmacology 50 (2006) 548-557
14. D'Souza D.C., Gil R., Cassello K., Morrissey K., Abi-Saab D., White J., Sturwold R., Bennett A., Karper L.P., Zuzarte E., Charney D.S., and Krystal J.H. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry 47 (2000) 450-462
15. Evins A.E., Fitzgerald S.M., Wine L., Rosselli R., and Goff D.C. Placebo-controlled trial of glycine added to clozapine in schizophrenia. American Journal of Psychiatry 157 (2000) 826-828
16. Flogel U., Niendorf T., Serkowa N., Brand A., Henke J., and Leibfritz D. Changes in organic solutes, volume, energy state, and metabolism associated with osmotic stress in a glial cell line: a multinuclear NMR study. Neurochemical Research 20 (1995) 793-802
17. Galli A., Mori F., Bargellini M., and Coppini L. Sodium-dependent release of exogenous glycine from preloaded rat hippocampal synaptosomes. Journal of Neural Transmission. General Section 93 (1993) 167-179
18. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., and Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 153 (1996) 1628-1630
19. Govindaraju V., Young K., and Maudsley A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR in Biomedicine 13 (2000) 129-153
20. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., and Bifone A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berlin) 201 (2008) 273-284
21. Gundlach A.L., and Beart P.M. Neurochemical studies of the mesolimbic dopaminergic pathway: glycinergic mechanisms and glycinergic-dopaminergic interactions in the rat ventral tegmentum. Journal of Neurochemistry 38 (1982) 574-581
22. Harsing Jr. L.G., Solyom S., and Salamon C. The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain. Neurochemical Research 26 (2001) 915-923
23. Hashimoto K., Fujita Y., Ishima T., Chaki S., and Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine. European Neuropsychopharmacology 18 (2008) 414-421
24. Hayashi Y., Ishibashi H., Hashimoto K., and Nakanishi H. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia 53 (2006) 660-668
25. Hejazi N., Zhou C., Oz M., Sun H., Ye J.H., and Zhang L. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Molecular Pharmacology 69 (2006) 991-997
26. Hejnum S., and Hassel B. High-affinity glycine and glutamate transport in pig forebrain white and gray matter: a quantitative study. Neurochemistry International 50 (2007) 696-702
27. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., and Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 169 (1996) 610-617
28. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry 56 (1999) 29-36
29. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biological Psychiatry 55 (2004) 165-171
30. Huang H., Barakat L., Wang D., and Bordey A. Bergmann glial GlyT1 mediates glycine uptake and release in mouse cerebellar slices. Journal of Physiology 560 (2004) 721-736
31. Hurd R., Sailasuta N., Srinivasan R., Vigneron D.B., Pelletier D., and Nelson S.J. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magnetic Resonance in Medicine 51 (2004) 435-440
32. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148 (1991) 1301-1308
33. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 151 (1994) 1234-1236
34. Javitt D.C., Silipo G., Cienfuegos A., Shelley A.M., Bark N., Park M., Lindenmayer J.P., Suckow R., and Zukin S.R. Adjunctive high-dose glycine in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 4 (2001) 385-391
35. Javitt D.C., Duncan L., Balla A., and Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Molecular Psychiatry 10 (2005) 276-287
36. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
37. Kanahara N., Shimizu E., Ohgake S., Fujita Y., Kohno M., Hashimoto T., Matsuzawa D., Shirayama Y., Hashimoto K., and Iyo M. Glycine and D:-serine, but not D:-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berlin) 198 (2008) 363-374
38. Karasawa J., Hashimoto K., and Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behavioural Brain Research 186 (2008) 78-83
39. Kaufman M.J., Henry M.E., Frederick B.deB., Hennen J., Villafuerte R.A., Stoddard E.P., Schmidt M.E., Cohen B.M., and Renshaw P.F. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biological Psychiatry 54 (2003) 534-539
40. Kessler M., Terramani T., Lynch G., and Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. Journal of Neurochemistry 52 (1989) 1319-1328
41. Kleckner N.W., and Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241 (1988) 835-837
42. Konradsson A., Marcus M.M., Hertel P., Svensson T.H., and Jardemark K.E. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 60 (2006) 102-108
43. Labrie V., Lipina T., and Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology (Berlin) 200 (2008) 217-230
44. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 62 (2005) 1196-1204
45. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., and Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biological Psychiatry 39 (1996) 213-215
46. Linn G.S., O'Keeffe R.T., Lifshitz K., Schroeder C., and Javitt D.C. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology (Berlin) 192 (2007) 27-38
47. Martin G., Guadano-Ferraz A., Morte B., Ahmed S., Koob G.F., De Lecea L., and Siggins G.R. Chronic morphine treatment alters N-methyl-D-aspartate receptors in freshly isolated neurons from nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 311 (2004) 265-273
48. Neumeister A., Carson R., Henry S., Planeta-Wilson B., Binneman B., Maguire R.P., Luckenbaugh D.A., D'Souza C., Krystal J.H., and Frost J.J. Cerebral metabolic effects of intravenous glycine in healthy human subjects. Journal of Clinical Psychopharmacology 26 (2006) 595-599
49. Ogg R.J., Kingsley P.B., and Taylor J.S. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. Journal of Magnetic Resonance B 104 (1994) 1-10
50. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 52 (1995) 998-1007
51. Potkin S.G., Jin Y., Bunney B.G., Costa J., and Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. American Journal of Psychiatry 156 (1999) 145-147
52. Prescot A.P., Frederick B.deB., Wang L., Brown J., Jensen J.E., Kaufman M.J., and Renshaw P.F. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0 T. Magnetic Resonance in Medicine 55 (2006) 681-686
53. Provencher S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic Resonance in Medicine 30 (1993) 672-679
54. Provencher S.W. LCModel and LCMgui User's Manual (2005) 163
55. Roberto M., Schweitzer P., Madamba S.G., Stouffer D.G., Parsons L.H., and Siggins G.R. Acute and chronic ethanol alter glutamatergic transmission in rat central amygdala: an in vitro and in vivo analysis. Journal of Neuroscience 24 (2004) 1594-1603
56. Rosse R.B., Theut S.K., Banay-Schwartz M., Leighton M., Scarcella E., Cohen C.G., and Deutsch S.I. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clinical Neuropharmacology 12 (1989) 416-424
57. Roux M.J., and Supplisson S. Neuronal and glial glycine transporters have different stoichiometries. Neuron 25 (2000) 373-383
58. Silk D.B., Kumar P.J., Perrett D., Clark M.L., and Dawson A.M. Amino acid and peptide absorption in patients with coeliac disease and dermatitis herpetiformis. Gut 15 (1974) 1-8
59. Stoll B., Henry J., Reeds P.J., Yu H., Jahoor F., and Burrin D.G. Catabolism dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed piglets. Journal of Nutrition 128 (1998) 606-614
60. Toth E., and Lajtha A. Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses. Neurochemical Research 6 (1981) 1309-1317
61. Toth E., and Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochemical Research 11 (1986) 393-400
62. Tsai G.E., Yang P., Chung L.C., Tsai I.C., Tsai C.W., and Coyle J.T. D-serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry 156 (1999) 1822-1825
63. Urenjak J., Williams S.R., Gadian D.G., and Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. Journal of Neuroscience 13 (1993) 981-989
64. Vengeliene V., Bachteler D., Danysz W., and Spanagel R. The role of the NMDA receptor in alcohol relapse: a pharmacological mapping study using the alcohol deprivation effect. Neuropharmacology 48 (2005) 822-829
65. Viola A., Chabrol B., Nicoli F., Confort-Gouny S., Viout P., and Cozzone P.J. Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia. Pediatric Research 52 (2002) 292-300
66. Waziri R. Glycine therapy of schizophrenia. Biological Psychiatry 23 (1988) 210-211
67. Williams J.B., Mallorga P.J., Conn P.J., Pettibone D.J., and Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophrenia Research 71 (2004) 103-112
68. Wojcik S.M., Katsurabayashi S., Guillemin I., Friauf E., Rosenmund C., Brose N., and Rhee J.S. A shared vesicular carrier allows synaptic corelease of GABA and glycine. Neuron 50 (2006) 575-587
69. Wu G. Intestinal mucosal amino acid catabolism. Journal of Nutrition 128 (1998) 1249-1252
70. Zafra F., Aragon C., Olivares L., Danbolt N.C., Gimenez C., and Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. Journal of Neuroscience 15 (1995) 3952-3969